Ardelyx, Inc.

ARDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2015 FY2014 FY2013 FY2012
Revenue $42.0M $24.0M $31.6M $28.9M $5.4M
Cost of Revenue $8.4M — — — —
Gross Profit $33.6M $24.0M — — —
Gross Margin 80.0% 100.0% — — —
Operating Expenses
Research & Development $75.5M $39.9M $25.9M $28.1M $10.2M
SG&A Expense $23.2M $13.5M $7.3M $3.7M $4.0M
Operating Income $-65.1M $-29.4M $-1.6M $-2.9M $-8.8M
Operating Margin -155.0% -122.3% -4.9% -9.9% -162.8%
Interest Expense — — — — —
Pretax Income $-63.2M $-29.7M $-3.1M $-6.4M $-9.8M
Income Tax Expense $1.2M $-29.0K $67.0K $141.0K —
Net Income $-64.3M $-29.6M $-3.2M $-6.6M $-9.8M
Net Margin -153.2% -123.3% -10.2% -22.7% -180.9%
EPS (Basic) $-1.36 $-1.29 $-0.31 $-5.82 $-11.32
EPS (Diluted) $-1.36 $-1.29 $-0.31 $-5.82 $-11.32
Shares Outstanding (Basic) 47.5M 26.0M 18.6M 1.2M —
Shares Outstanding (Diluted) 47.5M 26.0M 18.6M 1.2M —
Dividends Per Share — — — — —
← Newer Page 2 of 2 Older →